Is Protara Therapeutics Stock a Good Investment?
Protara Therapeutics Investment Advice | TARA |
- Examine Protara Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Protara Therapeutics' leadership team and their track record. Good management can help Protara Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceutical Products space and any emerging trends that could impact Protara Therapeutics' business and its evolving consumer preferences.
- Compare Protara Therapeutics' performance and market position to its competitors. Analyze how Protara Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Protara Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Protara Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Protara Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Protara Therapeutics is a good investment.
Sell | Buy |
Hold
Market Performance | Good | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Protara Therapeutics Stock
Researching Protara Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 51.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.77. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Protara Therapeutics recorded a loss per share of 2.64. The entity last dividend was issued on the 10th of January 2020. The firm had 1:40 split on the 10th of January 2020.
To determine if Protara Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Protara Therapeutics' research are outlined below:
| Protara Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (40.42 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protara Therapeutics currently holds about 98.46 M in cash with (37.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Protara Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Protara Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Protara Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Protara Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 62.71 M.Basic technical analysis of Protara Stock
As of the 29th of November, Protara Therapeutics holds the Semi Deviation of 2.75, coefficient of variation of 581.34, and Risk Adjusted Performance of 0.14. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Protara Therapeutics, as well as the relationship between them.Protara Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protara Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protara Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Protara Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Protara Therapeutics' Outstanding Corporate Bonds
Protara Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Protara Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Protara bonds can be classified according to their maturity, which is the date when Protara Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PL 1618 15 APR 26 Corp BondUS74368CBC73 | View | |
| US74368CAX20 Corp BondUS74368CAX20 | View | |
| US743674BE29 Corp BondUS743674BE29 | View | |
| US74368CAY03 Corp BondUS74368CAY03 | View | |
| PRXNA 3832 08 FEB 51 Corp BondUS74365PAE88 | View | |
| PL 5366 06 JAN 26 Corp BondUS74368CBQ69 | View | |
| PRXNA 4027 03 AUG 50 Corp BondUS74365PAD06 | View | |
| PRXNA 3257 19 JAN 27 Corp BondUS74365PAG37 | View |
Understand Protara Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Protara Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.14 | |||
| Market Risk Adjusted Performance | 1.91 | |||
| Mean Deviation | 3.39 | |||
| Semi Deviation | 2.75 | |||
| Downside Deviation | 3.3 | |||
| Coefficient Of Variation | 581.34 | |||
| Standard Deviation | 4.34 | |||
| Variance | 18.84 | |||
| Information Ratio | 0.1431 | |||
| Jensen Alpha | 0.6919 | |||
| Total Risk Alpha | 0.0831 | |||
| Sortino Ratio | 0.1883 | |||
| Treynor Ratio | 1.9 | |||
| Maximum Drawdown | 19.48 | |||
| Value At Risk | (4.98) | |||
| Potential Upside | 8.67 | |||
| Downside Variance | 10.88 | |||
| Semi Variance | 7.56 | |||
| Expected Short fall | (4.60) | |||
| Skewness | 0.793 | |||
| Kurtosis | 0.5834 |
| Risk Adjusted Performance | 0.14 | |||
| Market Risk Adjusted Performance | 1.91 | |||
| Mean Deviation | 3.39 | |||
| Semi Deviation | 2.75 | |||
| Downside Deviation | 3.3 | |||
| Coefficient Of Variation | 581.34 | |||
| Standard Deviation | 4.34 | |||
| Variance | 18.84 | |||
| Information Ratio | 0.1431 | |||
| Jensen Alpha | 0.6919 | |||
| Total Risk Alpha | 0.0831 | |||
| Sortino Ratio | 0.1883 | |||
| Treynor Ratio | 1.9 | |||
| Maximum Drawdown | 19.48 | |||
| Value At Risk | (4.98) | |||
| Potential Upside | 8.67 | |||
| Downside Variance | 10.88 | |||
| Semi Variance | 7.56 | |||
| Expected Short fall | (4.60) | |||
| Skewness | 0.793 | |||
| Kurtosis | 0.5834 |
Consider Protara Therapeutics' intraday indicators
Protara Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Protara Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Protara Therapeutics time-series forecasting models is one of many Protara Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Protara Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Protara Stock media impact
Far too much social signal, news, headlines, and media speculation about Protara Therapeutics that are available to investors today. That information is available publicly through Protara media outlets and privately through word of mouth or via Protara internal channels. However, regardless of the origin, that massive amount of Protara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Protara Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Protara Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Protara Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Protara Therapeutics alpha.
Protara Therapeutics Corporate Management
| MBA MPH | VP CoFounder | Profile | |
| Jesse Shefferman | Principal CoFounder | Profile | |
| Jathin MD | Executive Officer | Profile | |
| Justine OMalley | Senior Affairs | Profile | |
| Kristine Rosse | VP Officer | Profile | |
| Patrick MBA | Chief Officer | Profile | |
| Hannah Fry | Principal Controller | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Protara Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.